Peptide-Based Gastrointestinal Disorders Therapeutics
Market - Size, Share, Outlook, and Opportunity Analysis,
2018 – 2026
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-
based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of
various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel
syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide,
and Teduglutide received approval for the treatment of GIT disorders.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2028
Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic
constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of
guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate
cyclase C receptors in the intestine and is used for the treatment of chronic constipation and
irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide
(GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal
tract.
Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics
Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in
key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics
market growth over the forecast period.
For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug
Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug
is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food
and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is
a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel
syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).